Ownership and insider activity for Lyell Immunopharma, Inc. (LYEL): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial,...
Price
| Price | $10.78 |
| Market Cap | $264M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-10 | Shook David | S-Sale | 500 | $6K |
| 2026-09-10 | Aguirre Jarrad Mattieu | A-Award | 47,500 | $580K |
| 2026-08-31 | Aguirre Jarrad Mattieu | |||
| 2026-08-31 | Aguirre Jarrad Mattieu | 46,249 | $538K | |
| 2026-08-31 | Aguirre Jarrad Mattieu | 35,000 | $830K | |
| 2026-08-31 | Aguirre Jarrad Mattieu | 15,000 | $288K | |
| 2026-08-21 | Seely Lynn | S-Sale | 9,589 | $149K |
| 2026-08-21 | Hill Stephen J. | S-Sale | 989 | $15K |
| 2026-08-21 | Lee Gary K. | S-Sale | 1,457 | $23K |
| 2026-08-10 | Bulis Veronica Sanchez | S-Sale | 621 | $9K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $96.7M | $140.4M | $293.8M | $123.6M | $145.6M | $105.6M | $60.2M |
| Short-term Investments | $339.4M | $472.2M | $321.0M | $516.6M | $400.6M | $264.9M | $187.0M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $440.3M | $617.5M | $626.3M | $651.3M | $554.7M | $379.6M | $260.9M |
| Property, Plant & Equipment | $43.7M | $124.1M | $166.6M | $166.3M | $142.3M | $72.9M | $53.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $555.6M | $908.3M | $1.13B | $937.6M | $750.0M | $490.9M | $340.1M |
| Accounts Payable | $2.8M | $9.4M | $3.2M | $3.9M | $4.8M | $5.4M | $2.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $22.0M | $49.3M | $46.7M | $37.0M | $34.5M | $53.8M | $49.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $147.6M | $189.8M | $197.6M | $104.3M | $95.1M | $108.0M | $91.8M |
| Retained Earnings | -$129.7M | -$334.1M | -$584.4M | -$767.5M | -$1.00B | -$1.35B | -$1.62B |
| Total Equity | $408.1M | $718.4M | $929.8M | $833.3M | $655.0M | $382.8M | $248.2M |
| Total Debt | $27.5M | $54.6M | $67.8M | $67.7M | $63.2M | $59.0M | $51.0M |
| Net Debt | -$408.6M | -$558.0M | -$547.0M | -$572.5M | -$483.1M | -$311.6M | -$196.2M |
| Working Capital | $418.2M | $568.3M | $579.5M | $614.3M | $520.2M | $325.8M | $211.5M |
Financial Health
| Debt / Equity | 0.16 |
| Current Ratio | 5.36 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.46 |
Profitability
| Return on Equity | -91.62% |
| Return on Invested Capital | -70.80% |
| Return on Assets | -79.86% |
| Gross Margin | -8537.04% |
| Operating Margin | -711329.63% |
| Net Margin | -920285.19% |
Related companies: ACIU · ALDX · ALLO · AMRN · CABA · EDIT · GNLX
Explore sector: Healthcare · Biotechnology
More sections of LYEL: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks